Late Cardiac Death in Patients Undergoing Transcatheter Aortic Valve Replacement  by Poulin, Frédéric et al.
J A C C V O L . 6 6 , N O . 2 , 2 0 1 5 Letters
J U L Y 1 4 , 2 0 1 5 : 2 0 2 – 7
207*Heart Rhythm Management Centre
UZ Brussel-VUB
Laarbeeklaan 101
Brussels, 1090
Belgium
E-mail: giulioconte.cardio@gmail.com
http://dx.doi.org/10.1016/j.jacc.2015.04.061
Please note: The authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
RE F E RENCE S
1. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-deﬁbrillator
therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll
Cardiol 2015;65:879–88.
2. Sarkozy A, Chierchia GB, Paparella G, et al. Inferior and lateral electrocar-
diographic repolarization abnormalities in Brugada syndrome. Circ Arrhythm
Electrophysiol 2009;2:154–61.
3. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of con-
duction abnormality and a predictor of prognosis of Brugada syndrome. Cir-
culation 2008;118:1697–704.
4. Tokioka K, Kusano KF, Morita H, et al. Electrocardiographic parameters and
fatal arrhythmic events in patients with Brugada syndrome: combination of
depolarization and repolarization abnormalities. J Am Coll Cardiol 2014;63:
2131–8.
5. Roten L, Derval N, Sacher F, Pascale P, et al. Ajmaline attenuates electro-
cardiogram characteristics of inferolateral early repolarization. Heart Rhythm
2012;9:232–9.Late Cardiac Death in
Patients Undergoing
Transcatheter Aortic
Valve ReplacementIn the PARTNER (Placement of Aortic Transcatheter
Valve Trial) study, similar to other studies, mild,
moderate, or severe aortic regurgitation (AR) after
transcatheter aortic valve replacement (TAVR) was
associated with 1-year, all-cause mortality (1). In
the February 10, 2015, issue of the Journal, Urena
et al. (2) studied late cardiac death in a prospective
cohort of 3,726 TAVR patients. After a follow-up of
22  18 months, moderate or severe AR, using
VARC (Valve Academic Research Consortium)-2
criteria, occurred in 11% of patients and indepen-
dently predicted death due to advanced heart fail-
ure (HF). Although several mechanisms linking AR
and death post-TAVR have been proposed (3),
including bias due to confounding factors (AR as a
marker), this study by Urena et al. (2) tends
to suggest that AR is deleterious in itself (AR as the
cause), and could potentially lead to progression to
advanced HF.
We want to congratulate the investigators for
shedding light on an important issue and to shareour complementary ﬁndings. In our recent work,
the recovery of left ventricular (LV) myocardial
mechanics was analyzed at mid-term follow-up (5 
3 months) after TAVR in a cohort of 64 patients
(the transapical approach was used in 61%) using
speckle-tracking echocardiography (4). The pres-
ence of new mild AR and any moderate or severe
AR was associated with an increase in LV diastolic
and systolic volumes, lack of LV mass regression,
and the lack of improvement in global longitudinal
LV systolic strain, strain rate, and early dias-
tolic strain rate post-TAVR, as opposed to patients
without AR.
Therefore, not only does post-TAVR AR acutely
reduce forward stroke volume and increase LV end-
diastolic pressure, it also importantly prevents LV
structural and functional recovery at mid-term
follow-up. Pathophysiologically, the sudden change
from pressure overload to volume overload in a
concentric hypertrophied LV appears to blunt the
favorable LV remodeling that is expected to occur
following the resolution of chronic pressure overload
by TAVR. These observations elucidate the plausible
causal mechanisms linking post-TAVR AR to HF
events and support the intrinsic impact of post-
TAVR AR in modulating prognosis, as shown by
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